MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder
NEW YORK--(BUSINESS WIRE) Mar 07, 2024 -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada MMED), (the“Company” or“MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Anxiety | Canada Health | Clinical Trials | Generalized Anxiety Disorder (GAD) | Pharmaceuticals | Study